PTSD

The first results from Phase 3 trials testing MDMA-assisted psychotherapy for PTSD have been announced. The promising data are the first Phase 3 results to be revealed for any psychedelic-based therapy paving the way for a landmark FDA approval in 2023.

Surfing the wave of new research into medical uses for psychedelic compounds, the Icahn School of Medicine at Mount Sinai has launched a dedicated psychedelic center focusing on the study of MDMA and psilocybin for PTSD and other stress-related conditions.

For the first time in decades, a pilot study has explored the effects of MDMA therapy in couples within the framework of a robust clinical trial. Following on from ongoing research into MDMA-assisted therapy for PTSD, the results are promising.

The FDA has approved a platform called NightWare, designed to help improve sleep in post-traumatic stress disorder patients suffering from recurrent nightmares. The system is an Apple Watch app that will only be available by prescription.

Researchers have conducted the world’s first meta-analysis of the relationship between PTSD and dementia. Encompassing over a million subjects the study found PTSD can double a person’s risk of developing dementia in their senior years.

A new pilot study has demonstrated nitrous oxide, commonly known as laughing gas, may help military veterans suffering from PTSD. A larger trial is now underway after several studies demonstrated potential new uses for the gas.

A new study is looking at the long-term efficacy of MDMA-assisted psychotherapy for the treatment of PTSD, finding the substantial beneficial effects of the therapy hold strong for over a year and patients continue to improve after the MDMA sessions.

In research that could have implications for sufferers of post-traumatic stress disorder, scientists have found it is possible to effectively erase memories of a traumatic event in fruit flies by keeping them in the dark for two days.

Marking an impressive milestone in the development of MDMA-assisted psychotherapy for PTSD, the FDA has approved the treatment for Expanded Access, allowing certain patients access to the therapy before full market approval is granted.

A new research program from DARPA is looking to remove those pesky hallucinatory side effects from psychedelic medicines such as MDMA & psilocybin.

In one of the largest, and most detailed studies of its kind conducted to date, a team of researchers examined data from over 150,000 US war veterans and found eight specific genetic regions that seem to confer an increased risk of developing post-traumatic stress disorder (PTSD).

Researchers believe they have homed in on a specific biomarker that can be linked to suicidal thoughts in subjects suffering from post-traumatic stress disorder (PTSD). The new study adds to a growing body of research into novel ways clinicians can identify patients at high risk of suicide.